Pierre Fabre partners with XtalPi for AI-driven drug discovery using robotics
Pierre Fabre借助XtalPi的人工智能与机器人技术开展药物发现
On November 9, 2026, Laboratoires Pierre Fabre and XtalPi announced a partnership to identify novel small-molecule clinical candidates in oncology and potentially dermatology or rare diseases. XtalPi will handle de novo molecular design with its integrated AI and robotic platform, while Pierre Fabre will screen compounds and manage subsequent clinical development. The agreement includes upfront payments, milestone fees, and revenue sharing to accelerate discovery for historically difficult targets.
Source: Chinese robotics — Research news discovery · Read original article ↗
English translation unavailable. Choose the original article to read it.
What the source reports
Publisher-reported claims, with original evidence. These results have not been independently verified by RoboSignal.
- paper: not_reported
Source excerpts and review record
Automatically extracted; no manual editorial approval recorded.
Unite.AI Pierre Fabre借助XtalPi的人工智能与机器人技术开展药物发现 合作伙伴 将 Unite.AI 添加到您在 Google 上的首选来源 Laboratoires Pierre Fabre与XtalPi于2026年11月9日 宣布 达成协议，将在多个研究项目中发现新型小分子临床候选药物。
Open source S2
Source：Chinese robotics — Research news discovery · unite.ai